氨溴索对慢性阻塞性肺疾病急性加重期患者血清炎症因子的影响

目的:系统评价氨溴索注射液对慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效及对患者血清炎症因子CRP及TNF-α的影响。方法:①按照诊断标准共纳入60例患者,按入院或就诊的先后顺序随机分成氨溴索治疗组和对照组,每组30例患者;另设30名COPD稳定期患者作为稳定期对照组。②治疗前后抽取静脉血,待测CRP及TNF-α水平;③对照组患者仅给予抗菌药物及解痉平喘药物等常规治疗;治疗组患者给予常规治疗外,还给予盐酸氨溴索注射液30mg,每天分2次静滴,10天为1疗程;④治疗1疗程后观察临床疗效及血清炎症因子水平的变化。结果:①两组患者在性别,年龄,病程,病情,合并疾病的分布等基线资料上无显著性差异,P>0.05;②AECOPD患者机体炎症因子水平较COPD稳定期患者显著升高,P<0.01;氨溴索治疗组无论在临床疗效抑或降低血清炎症因子水平方面均要优于对照组,P<0.05。结论:盐酸氨溴索注射液辅助治疗可显著降低AECOPD患者血清炎症因子水平,提高临床疗效。

The Effects of Ambroxol to the Inflammatory Factor of the Acute Exacerbation Chronic Obstructive Pulmonary Disease

Objective: Systematic evaluation the clinical efficacy of Ambroxol injection on chronic acute exacerbation of obstruc-tive pulmonary disease(AECOPD) and the effects to patient serum CRP and inflammatory cytokines TNF-α.Methods: 60 COPD patients were randomly divided into ambroxol treatment group and control group,each group contained 30 patients;besides,the other 30 stable COPD patients as stable group.Control patients only received antibiotics and antispasmodic drugs and other conventional asthma therapy;treatment group were given conventional treatment,but also given Ambroxol Injection 30mg,2 times a day intravenously for 10 days as a course of treatment.Before and after treatment,the serum levels of CRP and TNF-α were measured.Results: The baseline in-formation,age,disease duration,patient’s condition,concomitant diseases hade no significant difference between the two groups,P> 0.05.Compared with stable COPD patients,the levels of inflammatory cytokine in AECOPD patients were significantly increased,P <0.01.Ambroxol treatment could significantly improve the clinical efficacy and reduce of serum levels of inflammatory cytokines,com-pared with control group,P<0.05.Conclusion: Ambroxol treatment can significantly improve the clinical efficacy and reduction of serum levels of inflammatory cytokines.